Price of New A.L.S. Treatment Will Be $158,000 Per Year, Maker Saysnews2022-09-30T20:16:18+00:00September 30th, 2022|The New York Times|
Un nuevo tratamiento contra el VIH ha probado ser un éxito. ¿Será accesible en África?news2022-09-30T09:00:20+00:00September 30th, 2022|The New York Times|
FDA Approves ALS Treatment Despite Questions About Effectivenessnews2022-09-29T21:14:36+00:00September 29th, 2022|The New York Times|
Alzheimer’s Drug Slows Cognitive Decline in Key Studynews2022-09-28T13:42:59+00:00September 28th, 2022|The New York Times|
A New Shot Guards Against H.I.V., but Access for Africans Is Uncertainnews2022-09-27T07:00:12+00:00September 27th, 2022|The New York Times|
Biogen Agrees to Pay $900 Million to Settle Lawsuit Over Kickbacksnews2022-09-27T00:35:45+00:00September 27th, 2022|The New York Times|
Monkeypox Appears to Recede, but Risks and Uncertainties Lingernews2022-09-26T09:00:17+00:00September 26th, 2022|The New York Times|
Weekly Health Quiz: Broken Hearts, Anxiety and Exercisenews2022-09-22T21:50:41+00:00September 22nd, 2022|The New York Times|
